Page 66 - CPG endometrial cancer
P. 66
พญ.จิราวดี รว่ มเจรญิ ชยั
26. Yang X, Leslie G, Doroszuk A, et al. Cancer
risks associated with germline palb2 pathogenic
variants: An international study of 524 families. J
Clin Oncol. 2020; 38(7):674-85.
27. Mavaddat N, Dorling L, Carvalho S, et al.
Pathology of tumors associated with pathogenic
germline variants in 9 breast cancer susceptibility
genes. JAMA Oncol. 2022;8(3):e216744.
28. Hu C, Hart SN, Gnanaolivu R, et al. A
population-based study of genes previously
implicated in breast cancer. N Engl J Med.
2021;384(5):440-51.
29. Yadav S, Boddicker NJ, Na J, et al.
Contralateral breast cancer risk among
carriers of germline pathogenic variants in
atm, brca1, brca2, chek2, and palb2. J Clin
Oncol. 2023;41(9):1703-13.
30. Morra A, Mavaddat N, Muranen TA, et al.
The impact of coding germline variants on
contralateral breast cancer risk and survival.
Am J Hum Genet. 2023;110(3): 475-86.
31. Norquist BM, Harrell MI, Brady MF, et al.
Inherited mutations in women with ovarian
carcinoma. JAMA Oncol. 2016;2(4): 482-90.
57
